FDA staff members gave a mixed review of AstraZeneca and Bristol-Myers Squibb's dapagliflozin, saying the drug candidate works against diabetes but poses serious risks. Trial data showed a higher incidence of breast and bladder cancer in dapagliflozin users, and the medicine appeared less effective in those with impaired kidney function, the agency said. An advisory panel is scheduled Tuesday to review the drug.

Full Story:
Bloomberg, Reuters

Related Summaries